Immunogenicity of Anaplasma marginale type IV secretion system proteins in a protective outer membrane vaccine.
about
Comparative Proteomic Profiling of Ehrlichia ruminantium Pathogenic Strain and Its High-Passaged Attenuated Strain Reveals Virulence and Attenuation-Associated ProteinsAnaplasma marginale: Diversity, Virulence, and Vaccine Landscape through a Genomics ApproachProteomic profiling of the outer membrane fraction of the obligate intracellular bacterial pathogen Ehrlichia ruminantiumImmunogenicity of hypothetical highly conserved proteins as novel antigens in Anaplasma marginale.Structure of the type IV secretion system in different strains of Anaplasma phagocytophilum.Biological diversity of prokaryotic type IV secretion systems.Global transcriptional analysis reveals surface remodeling of Anaplasma marginale in the tick vector.Anaplasma marginale type IV secretion system proteins VirB2, VirB7, VirB11, and VirD4 are immunogenic components of a protective bacterial membrane vaccine.Phylogenomics reveals a diverse Rickettsiales type IV secretion system.Identification of Anaplasma marginale type IV secretion system effector proteinsIdentification of Anaplasma marginale outer membrane protein antigens conserved between A. marginale sensu stricto strains and the live A. marginale subsp. centrale vaccine.Association and evidence for linked recognition of type IV secretion system proteins VirB9-1, VirB9-2, and VirB10 in Anaplasma marginale.Immunogenicity of Outer Membrane Proteins VirB9-1 and VirB9-2, a Novel Nanovaccine against Anaplasma marginale.Breadth of the CD4+ T cell response to Anaplasma marginale VirB9-1, VirB9-2 and VirB10 and MHC class II DR and DQ restriction elementsVirB12 is a serological marker of Brucella infection in experimental and natural hosts.Physical linkage of naturally complexed bacterial outer membrane proteins enhances immunogenicity.Four VirB6 paralogs and VirB9 are expressed and interact in Ehrlichia chaffeensis-containing vacuoles.Comparison of genomes of Brucella melitensis M28 and the B. melitensis M5-90 derivative vaccine strain highlights the translation elongation factor Tu gene tuf2 as an attenuation-related gene.Bacterial type IV secretion systems in human disease.Nanoparticle-Based Delivery of Anaplasma marginale Membrane Proteins; VirB9-1 and VirB10 Produced in the Pichia pastoris Expression SystemAdaptive immunity to Anaplasma pathogens and immune dysregulation: implications for bacterial persistence.IgG and IgG2 antibodies from cattle naturally infected with Anaplasma marginale recognize the recombinant vaccine candidate antigens VirB9, VirB10, and elongation factor-Tu.Identification of a T-Cell Epitope That Is Globally Conserved among Outer Membrane Proteins (OMPs) OMP7, OMP8, and OMP9 of Anaplasma marginale Strains and with OMP7 from the A. marginale subsp. centrale Vaccine Strain.Anaplasma phagocytophilum outer membrane protein A interacts with sialylated glycoproteins to promote infection of mammalian host cellsMultistrain genome analysis identifies candidate vaccine antigens of Anaplasma marginale.Immunization-induced Anaplasma marginale-specific T-lymphocyte responses impaired by A. marginale infection are restored after eliminating infection with tetracycline.CD4 T cell antigens from Staphylococcus aureus Newman strain identified following immunization with heat-killed bacteria.CD4 T-cell epitopes associated with protective immunity induced following vaccination of mice with an ehrlichial variable outer membrane protein.Immune response of calves inoculated with proteins of Anaplasma marginale bound to an immunostimulant complex.Impact of Three Different Mutations in Ehrlichia chaffeensis in Altering the Global Gene Expression Patterns.
P2860
Q27334359-B119FD85-82A3-4A80-A068-E56C25B54A33Q28074461-CF1B7081-AD52-41E9-B4DF-5126B6D0570EQ28543634-306CF88F-9DB2-412E-B399-93143AD68439Q30153495-FF9E98A4-6291-4955-ACDF-EEFBDC70E1E2Q30533216-A78135E2-3E17-4BBC-A8B0-FAB7C795981CQ30927042-83A667B8-7C1B-4239-AEAC-7B8EDE39EC25Q33617357-F71F497D-0815-42B0-83CD-A91862F6BF59Q33676020-F0BD21DA-9240-42B5-B853-B35F35129364Q33826043-F462AC6A-1288-47EC-BBD8-AD07EC5D44EFQ34091037-527256C7-2448-4490-9AE3-855835033FB6Q34739801-9C10C38F-84F3-402B-A747-295517587642Q35665455-6BF5AF61-2A8D-416D-8240-C01527661454Q35999402-F6136EC0-0B8A-47F9-9753-40ACB2C25E31Q36025056-7F2612B2-21A7-4395-BD80-F952A8434F63Q36452324-6B3CD4ED-AB1C-425D-867A-05FB3674D549Q36483567-9E012A83-E35C-41F2-9EF9-5166118EC0B2Q37033432-47FDAB43-0491-4E64-93CB-5FFEC909853AQ37036048-4D3A8DD3-305E-4640-B99B-20C822432257Q37445142-42FA20FF-0F36-486E-A8E6-3EEA57CE26D4Q37594405-29F3C534-7937-4FDB-ADEC-13B4D8769D48Q37973905-C989FA59-D8C2-4FED-AF65-559456060A40Q38878619-E7F1E998-BB9C-4315-83DB-6F39C700D6CAQ40842064-D95D560B-EC38-456B-A39F-8D006A24986EQ41584877-666849DF-715D-46BC-8E44-FD7BC2EC0C6AQ41965635-F19E7E1F-E37E-4663-B962-9E724EC6D970Q42043972-A587967E-9B53-47E0-9F96-AC8DAE9E8597Q42109044-9C62BBA2-87EC-4138-9B2E-AFD1DFD7E943Q42909614-A2BD613B-0B4B-4ADA-9C38-28CBD6E7E32AQ43426240-AEBE944A-FAEA-4CA6-938E-8B1CCD478935Q52579481-6443F168-C4CA-4C5E-8C7D-15B4841CF5CC
P2860
Immunogenicity of Anaplasma marginale type IV secretion system proteins in a protective outer membrane vaccine.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Immunogenicity of Anaplasma ma ...... ective outer membrane vaccine.
@ast
Immunogenicity of Anaplasma ma ...... ective outer membrane vaccine.
@en
type
label
Immunogenicity of Anaplasma ma ...... ective outer membrane vaccine.
@ast
Immunogenicity of Anaplasma ma ...... ective outer membrane vaccine.
@en
prefLabel
Immunogenicity of Anaplasma ma ...... ective outer membrane vaccine.
@ast
Immunogenicity of Anaplasma ma ...... ective outer membrane vaccine.
@en
P2093
P2860
P356
P1476
Immunogenicity of Anaplasma ma ...... ective outer membrane vaccine.
@en
P2093
Guy H Palmer
Job E Lopez
Kelly A Brayton
Stephanie E Leach
Wendy C Brown
P2860
P304
P356
10.1128/IAI.00061-07
P407
P577
2007-03-05T00:00:00Z